There are 2137 resources available
541P - Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3
Presenter: Paul Mcsheehy
Session: E-Poster Display
Resources:
Abstract
542P - Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
Presenter: Antoine Italiano
Session: E-Poster Display
Resources:
Abstract
543P - Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Alexander Drilon
Session: E-Poster Display
Resources:
Abstract
544P - Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
Presenter: Chigusa Morizane
Session: E-Poster Display
Resources:
Abstract
545P - Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: E-Poster Display
Resources:
Abstract
546P - Innovative medicine in rare cancer: Perceived value of adaptive trials and surrogate endpoints for clinical decisions
Presenter: Andriy Krendyukov
Session: E-Poster Display
Resources:
Abstract
547P - Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)
Presenter: Timothy Yap
Session: E-Poster Display
Resources:
Abstract
548P - Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT)
Presenter: Ivan Victoria Ruiz
Session: E-Poster Display
Resources:
Abstract
549P - Identification of RET rearrangement in 12888 Chinese lung cancer patients by next-generation sequencing (NGS)
Presenter: Yuning Han
Session: E-Poster Display
Resources:
Abstract
550P - Preclinical characterization of CPL304110 as a potential selective inhibitor of fibroblast growth factors 1/2/3 in solid cancers
Presenter: Delfina Popiel
Session: E-Poster Display
Resources:
Abstract